血清降钙素原在慢性肝脏疾病中的研究进展  

Research progress of the serum procalcitonin in patients with chronic hepatic disease

作　　者：詹柱 张琼方[1] 曾维琼[1] 

机构地区：[1]重庆医科大学附属第二医院感染病科,重庆400010

出　　处：《重庆医科大学学报》2015年第3期325-328,共4页Journal of Chongqing Medical University

基　　金：国家"十二.五"重大科技专项资助项目(编号:2012ZX10002007001)

摘　　要：降钙素原(procalcitonin,PCT)是严重的细菌感染和脓毒症的诊断标志物,目前已被广泛应用于临床。在慢性肝脏疾病患者中,PCT的生物合成是否受到肝脏疾病的影响还不明确,有部分研究肯定了PCT对肝硬化并发感染及自发性腹膜炎的诊断价值,但也有部分研究持否定态度。在一些特殊情况下,比如自身免疫性肝炎、肝移植术后、原发性肝癌广泛转移等情况下,PCT可能异常升高。通过连续动态监测及结合其他指标综合评价,PCT对治疗效果和预后评估有一定价值,对抗生素使用的指导价值仍不明确。Procalcitonin（PCT）is a diagnostic biomarker of severe bacterial infection and sepsis and it has been widely used in clinical diagnosis. Whether PCT biosynthesis is affected by the liver disease is uncertain. Some researches revealed that serum PCT was eligible for diagnosing infection accompanied with liver cirrhosis,but some researches disagreed. The level of serum PCT might unusually increase in patients with autoimmune hepatitis or after liver transplantation or with extensive metastatic deposits in liver.Monitoring serum PCT consecutively and dynamically,as well as comprehensive assessment in combination with other makers are valuable in judging the treatment effect and estimating the prognosis,however,its role in guiding the rational use of antibiotics is still uncertain.

关 键 词：降钙素原 肝脏疾病 

分 类 号：R446.1[医药卫生—诊断学]